Mannatech patents prevail again
This article was originally published in The Tan Sheet
Executive Summary
The U.S. District Court for the Northern District of Texas prohibits Green Life and Xiong Lo from making, selling or distributing products infringing certain of Mannatech's patents. The Coppell, Texas, firm said Dec. 18 Green Life and Xiong Lo had purchased the Glyco 8 supplement from Boston Mountain Labs, against which Mannatech already prevailed in a separate patent case (1"The Tan Sheet" Oct. 12, 2009, In Brief)
You may also be interested in...
Mannatech wins patent suit
As result of litigation to protect its patented glyconutrient products Ambrotose complex and Advanced Ambrotose formulas, the Coppell, Texas-based dietary supplements marketer announces that the U.S. District Court for the Northern District of Texas entered a final judgment and permanent injunction against Boston Mountain Laboratories, banning the firm from making or selling certain products for the duration of several of Mannatech's U.S. patents. Specifically, Boston Mountain Labs cannot sell BML Glyconutrient Formula, Glyco-8 and Glycoessentials, among others. Last year, the firm won patent and trademark claims it brought against Glycobiotics International for its infringing product Glycomannan (1"The Tan Sheet" July 21, 2008)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.